Send us a text ([ Ссылка ])

The Oncology Journal Club - Delivering Oncology News Differently

The Oncology Podcast, brought to you by Oncology News Australia ([ Ссылка ]) , is proud to present Episode 33 in our series The Oncology Journal Club.

Was Beethoven's death the result of medical malpractice? This week the OJC team tackle this crucial question plus the microbiome, trial design bias, five year outcomes for metastatic non-small-cell lung cancer and much more...

Hans Prenen gets us started by talking us through the connection between the gut microbiome and immune checkpoint inhibitors and Eva Segelov has a mega paper this week…  She tackles our friend Bishal Gyawali’s paper addressing biases in study design that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale. Fascinating stuff!

Then Craig Underhill gives us his thoughts on Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer.

Today’s quick bites are as diverse as ever covering highlights from the AACR ASM, Fecal transplants for patients with cachexia, the TAPUR trial, Controversies in Thoracic Oncology, the costs of fear of cancer recurrence and much more.

With the usual top quality banter, papers you won’t hear of anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club!

Full bios and the list of all papers discussed are available on our website ([ Ссылка ]) .

For the latest oncology news visit www.oncologynews.com.au ([ Ссылка ]) and for regular oncology updates for healthcare professionals, subscribe for free to get the weekly The Oncology Newsletter ([ Ссылка ]) .

The Oncology Podcast - An Australian Oncology Perspective

свернуть